|
2026 Conference Publication Su1603 As severe as ASUC? Clinical findings from a large cohort of moderately severe acute ulcerative colitis inpatientsEtchegaray, Amirah, Goetz, Naeman, Hanigan, Katherine, Tambakis, George, Phillips, Jennifer, Kumar, Rina, Radford-Smith, Graham, Walker, Gareth and Croft, Anthony (2026). Su1603 AS SEVERE AS ASUC? CLINICAL FINDINGS FROM A LARGE COHORT OF MODERATELY SEVERE ACUTE ULCERATIVE COLITIS INPATIENTS. Gastrointestinal Endoscopy, 103 (5), S-1094. doi: 10.1016/s0016-5107(26)02741-0 |
|
2026 Conference Publication Su1603 AS SEVERE AS ASUC? CLINICAL FINDINGS FROM A LARGE COHORT OF MODERATELY SEVERE ACUTE ULCERATIVE COLITIS INPATIENTSEtchegaray, Amirah, Goetz, Naeman, Hanigan, Katherine, Tambakis, George, Phillips, Jennifer, Kumar, Rina, Radford-Smith, Graham, Walker, Gareth and Croft, Anthony (2026). Su1603 AS SEVERE AS ASUC? CLINICAL FINDINGS FROM A LARGE COHORT OF MODERATELY SEVERE ACUTE ULCERATIVE COLITIS INPATIENTS. Elsevier BV. doi: 10.1016/s0016-5085(26)02810-6 |
|
2026 Conference Publication As severe as Acute Severe Ulcerative Colitis (ASUC)? Clinical findings from a large cohort of moderately severe acute ulcerative colitis inpatientsEtchegaray, A, Goetz, N, Hannigan, K, Phillips, J, Kumar, R, Tambakis, G, Radford-Smith, G, Walker, G and Croft, A (2026). P0276 As severe as Acute Severe Ulcerative Colitis (ASUC)? Clinical findings from a large cohort of moderately severe acute Ulcerative Colitis inpatients. Journal of Crohn’s and Colitis, 20 (Supplement_1) jjaf231.457. doi: 10.1093/ecco-jcc/jjaf231.457 |
|
2026 Conference Publication P0776 The likelihood of early infliximab failure (LEIF) score for day two prediction of infliximab failure in acute ulcerative colitisGoetz, N, Etchegaray, A, Tambakis, G, Phillips, J, Kumar, R, Brown, A, Radford-Smith, G, Walker, G, Croft, A and RBWH IBD Research Group (2026). P0776 The Likelihood of Early Infliximab Failure (LEIF) Score for Day Two Prediction of Infliximab Failure in Acute Ulcerative Colitis. Journal of Crohn’s and Colitis, 20 (Supplement_1) jjaf231.957. doi: 10.1093/ecco-jcc/jjaf231.957 |
|
2026 Conference Publication Unmasking the faces of Severe Colitis: A data-driven approach to defining Ulcerative Colitis phenotypes and predicting clinical outcomesEtchegaray, A, Goetz, N, Okano, S, Hartel, G, Hanigan, K, Phillips, J, Kumar, R, Tambakis, G, Brown, A, Radford-Smith, G, Walker, G and Croft, A (2026). P0339 Unmasking the faces of Severe Colitis: A data-driven approach to defining Ulcerative Colitis phenotypes and predicting clinical outcomes. Journal of Crohn’s and Colitis, 20 (Supplement_1) jjaf231.520. doi: 10.1093/ecco-jcc/jjaf231.520 |
|
2025 Conference Publication An algorithm for the early identification of acute ulcerative colitis inpatients requiring dose-accelerated infliximab inductionEtchegaray, Amirah, Goetz, Naeman, Hanigan, Katherine, Radford-Smith, Graham, Walker, Gareth and Croft, Anthony (2025). An algorithm for the early identification of acute ulcerative colitis inpatients requiring dose-accelerated infliximab induction. World Gastroenterology Organisation and Gastroenterological Society of Australia World Congress of Gastroenterology, Melbourne, VIC, Australia, 19–22 September, 2025. Richmond, VIC, Australia: John Wiley & Sons, Inc.. doi: 10.1111/jgh.70044 |
|
2024 Conference Publication Sequential rescue therapy with Janus kinase-inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitisEtchegaray, Amirah, Tambakis, George, Croft, Anthony, Radford-Smith, Graham and Walker, Gareth (2024). Sequential rescue therapy with Janus kinase-inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case seriesSwe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experienceGilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case reportEtchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease studyEtchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT studyAnandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
